Iterum Therapeutics Plc (NASDAQ:ITRM) currently has a daily average trading volume of 304.49K but it saw 943184 shares traded in last market. With a market cap of 26.57M USD, the company’s current market price of $1.17 came rising about 4.46 while comparing to the previous closing price of $1.12. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.50 and as low as $0.62. In the recent trading on the day, stock has struck highest price mark of $1.0901 while lowest mark touched by it was $1.22.
Taking a look at 20-day trading activity of Iterum Therapeutics Plc (ITRM) gives us an average price of $1.0386, while its current price level is -53.20% below from 52-week high level whereas it is 88.10% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.0971 while that of 200 days or SMA-200 reads an average of $1.3693. A closer look into the stock’s movement over the week reveals that its volatility is standing at 11.56% during that period while stretching the period over a month that decreases to 8.25%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 60.10 which implies that the stock is in neutral territory.
H.C. Wainwright upgraded its recommendation for the stock as a “Buy” from “Neutral” on March 15, 2021 while assigning a price target of $2.50. RBC Capital Mkts issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $7 and $2.
Over the week, ITRM’s stock price is moving 7.34% up while it is 9.35% when we observe its performance for the past one month. Year-to-date it is -40.61% down and over the past year, the stock is showing an upside performance of 78.63%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.3 beat the consensus estimate of -0.91 for the same. The company is expected to be releasing its next quarterly report in November, for which analysts forecasted an EPS of -0.2 while estimate for next year EPS is -1.11.
Currently, Iterum Therapeutics Plc’s total number of outstanding shares is 22.71M. Company’s return on equity (ROE) at -555.68%. Stock’s beta reads 2.28. Its return on asset (ROA) is -86.93% on average.
